ALLOS PHARMA
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and intellectual disabilities. The โmGluR theory of fragile Xโ proposed by MIT Professor Mark Bear and collaborators in 2004 is widely considered to be a key conceptual breakthrough, and laid the foundation for development of disease-modifying therapies for treatment of Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to develop and market the first approved therapy in Fragile X Syndrome.
ALLOS PHARMA
Industry:
Health Care Life Science Medical Neuroscience Pharmaceutical
Founded:
2019-01-01
Website Url:
http://www.allospharma.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Gravatar Profiles Danish Server Location
Similar Organizations
dRx Capital
Novartis Digital Health Venture Capital
Estro technologies s.r.l.
Technologies for neurodevelopmental disorders
Genevant
Delivering solutions through RNA therapeutics.
GreenCom
We make our future green and safe.
Instapill
Wholesale Over The Counter Naturals
Neurochlore
Neurochlore develops therapeutic method to treat developmental brain disorders.
Palo Santo Fund
Palo Santo Fund is an investment fund that invests in psychedelic and healthcare industry.
Sensus Drug Development Corporation
Sensus Drug Development Corp.
Current Employees Featured
Official Site Inspections
http://www.allospharma.com
- Host name: webcluster7.webpod10-cph3.one.com
- IP address: 77.111.240.70
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Allos Pharma"
ABOUT - Allos Pharma
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and โฆSee details»
Allos Pharma - Crunchbase Company Profile & Funding
Contact Email [email protected] We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and โฆSee details»
Allos Pharma Company Profile | Management and Employees List
Allos Pharma Profile and History. Our work spans three decades of research in neuroscience and intellectual disabilities. The "mGluR theory of fragile X" proposed by MIT Professor Mark Bear โฆSee details»
Allos Pharma, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Www.allospharma.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. ... The โฆSee details»
Allos Pharma - LinkedIn
Allos Pharma | 133 followers on LinkedIn. Pioneering Therapeutics for Neurodevelopmental Disorders. | We are a global team dedicated to improve the lives of patients with Fragile X โฆSee details»
Allos Pharma - VentureRadar
Website: https://www.allospharma.com/ Allos Pharma Inc. is a biopharmaceutical company dedicated to the development of treatments for rare neurological disorders.See details»
Allos Pharma - Company Profile - Tracxn
Oct 20, 2024 Allos Pharma is the eveloper of therapeutics for neurological disorders. It is developing the therapeutics for multiple neurological disorders such as Fragile X Syndrome โฆSee details»
Allos Pharma - Overview, News & Similar companies - ZoomInfo
Who is Allos Pharma. Our work spans three decades of research in neuroscience and intellectual disabilities. The "mGluR theory of fragile X" proposed by MIT Professor M ark Bear and โฆSee details»
Allos Pharma Information - RocketReach
Allospharma.com; mit.edu; 1 617374XXXX; View Similar People. Related Companies Mayo Clinic School of Medicine. 389 Cityblock Health. 1,039 $467.3m Florida Combined Life Insurance โฆSee details»
Allos Pharma Inc. presents new positive data analyses at the 18th โฆ
By Allospharma July 14, 2022 May 30th, 2023 No Comments. CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ โ Allos Pharma Inc (โAllosโ), a late-stage pharmaceutical company developing โฆSee details»
Allos Pharma, Inc.:Company Profile & Technical โฆ
Allos Pharma is a company that provides Neurodevelopmental disorder and more. Allos Pharma is headquartered in US . Allos Pharma was founded in 2019.See details»
Allos Pharma Inc. Receives FDA Guidance for the Design of a โฆ
By Allospharma May 23, 2023 May 30th, 2023 No Comments CAMBRIDGE, Mass., May 23, 2023 /PRNewswire/ โ Allos Pharma Inc. (โAllosโ), a biopharmaceutical company specializing in the โฆSee details»
Randall Carpenter - Co-Founder @ Allos Pharma - Crunchbase
Randall Carpenter is the Co-Founder at Allos Pharma.. He attended United States Public Health Service Hospital, San Francisco, CA.See details»
Allos Pharma: Employee Directory | ZoomInfo.com
Allos Pharma Contact Info: Website: www.allospharma.com What does Allos Pharma do? Our work spans three decades of research in neuroscience and intellectual disabilities. The โฆSee details»
Allos Pharma - Company Information, Competitors, News & FAQs
Find useful insights on Allos Pharma's company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at Allos Pharma.See details»
Allos โ Allos Pharma
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and โฆSee details»
News - Allos Pharma
By Allospharma Allos. Allos announced presentation of โArbaclofen produces clinically meaningful improvements in individuals with Fragile Xโ at the 18th NFXF International Fragile X โฆSee details»
Allos Pharma, Inc. (Allos Pharma, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ โฆ
CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Allos Pharma Inc. ("Allos"), a biopharmaceutical company specializing in the development of treatments for rare โฆSee details»
Allos Pharma secures exclusive license on arbaclofen in Fragile X ...
Nov 19, 2020 For more information visit www.allospharma.com. Allospharma. Previous Post Allos Pharma Inc. presents new positive data analyses at the 18th NFXF International Fragile โฆSee details»